Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia

N/ACompletedNCT02206243

Jena University Hospital300 enrolled

Overview

The purpose of this observational study is to evaluate the prostatic arterial embolization (PAE) with Embozene® Microspheres (Boston Scientific) in sphere sizes of 250 µm for the treatment of symptomatic benign prostatic hyperplasia (BPH).

EmboProstate is an observational study that collects data of patients with benign prostatic hyperplasia that are treated with 250 µm Embozene ® Microspheres (Boston Scientific). The study evaluates the efficacy and safety of the microspheres for prostatic arterial embolization for benign prostata hyperplasia treatment. 10 adult male subjects will be enrolled in this study. If eligible patients are recruited, they will undergo the prostate artery embolization procedure in our radiology department. Once the catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected embospheres will slow the blood flow to the prostate reducing urinary tract symptoms caused by BPH. Within one week after PAE as well as after one, three and six months post-procedure an MRI examination ill occur. A follow-up visit using a questionnaire is due after 6 months.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Benign Prostatic Hyperplasia

Interventions

Embozene MicrospheresDRUG

Intraarterial application

Eligibility

Sex: MALEMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male * adults \> 40 years old * severe symptomatic BPH with IPSS \> 18 and/or QoL \> 3 or maximum urinary flow rate (Qmax) ≤ 15 ml/sec or transurethral catheter for retention * no improvement after or intolerance of medical treatment for at least six months * prostatic volume \> 30 cm³ Exclusion Criteria: * female * less than 40 years old * eGFR \< 45 ml/min \* m² * suspicion of prostatic malignancy * prostatic malignancy * acute prostatitis or cystitis * hydronephrosis * bladder stone or bladder diverticulum * urethral stenosis * major surgery within 4 weeks prior to the screening visit * active clinically serious infection * progressive arteriosclerosis * contraindications against angiography

Locations (1)

Department of Radiology, University Hospital Jena

Jena, Thuringia, Germany

Outcomes

Primary Outcomes

Symptomatic improvement of BPH symptoms (= International Prostate Symptom Score (IPSS) < 18 and reduction > 25% QoL (Quality of Life) < 4 & reduction ≥ & / or Qmax > 15 ml/s & increase of Qmax ≥ 3,0ml/s) at 6 and 12 months post intervention

Improvement of feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia

Time frame: Baseline, follow-up after 1 months, 6 months, 12 months, 24 months

Secondary Outcomes

Evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)

The number and the severity of adverse events will be recorded to evaluate the safety of prostate artery embolization. Events will be reported by subjects within the 1st week after PAE and at follow-up after 6 months.

Time frame: Within 1st week after PAE and follow-up after 1 months, 6 months, 12 months, 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.